מעבדת מחקר בגידולים נוירואנדוקריניים
פעילות מעבדה מוקדשת לחקר המנגנונים המולקולריים בהתפתחות גידולים נוירואנדוקריניים בבני האדם
חברי הקבוצה:
פרופ' סימונה גלסברג - MD
ד"ר שני אבניאל-פולק
פרופ' דוד גרוס - MD
ד"ר קירה אולייניקוב - MD
רובה סימאן, סטודנטית למסטר
ד"ר עדי גור ארי - מתמחה
Research Projects
The effect of mTOR inhibitors in combination with autophagy inhibitors on NET cells - as a new possible effective therapy to overcome treatment resistance for NET patients
Positive Modulation of Expression of the Type 2 Somatostatin Receptor (SSTR2) in tumors of patients with NETs - a means towards improving therapy with somatostatin analogues
Clinical Studies
.(TELESTAR and TELECAST studies, two international phase III double-blind placebo-controlled studies aiming to assess the possible efficacy of a new drug called telotristat ethyl (a serotonin synthesis inhibitor) in patients who have symptoms of carcinoid syndrome that are not controlled with other drugs (completed
.(A double blind, phase III trial comparing cabozantinib (a tyrosine kinase inhibitor) with placebo in patients with progressive metastatic medullary thyroid carcinoma, to assess progression-free survival (PFS
Publications PUBMED
https://www.ncbi.nlm.nih.gov/pubmed/?term=Grozinsky-Glasberg+S
https://www.ncbi.nlm.nih.gov/pubmed/?term=gross+David
מחקר ה-SORENTO:
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
Active center; active patient recruitement
https://classic.clinicaltrials.gov/ct2/show/NCT05050942